Clinical trial · Interventional
Topotecan and Melphalan for Retinoblastoma
Choice of Topotecan or Melphalan in Retinoblastoma Patients
NCT04799002CI-TRIAL-00050682recruitingPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Effect | — | UNRESOLVED | — |
| Retinoblastoma | Retinoblastoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Topotecan
- description
- Topotecan intraocular injection during chemotherapy
- interventionNames
- Drug: Topotecan
- type
- EXPERIMENTAL
- label
- Melphalan
- description
- Melphalan intraocular injection during chemotherapy
- interventionNames
- Drug: Melphalan
Primary outcomes (1)
- measure
- Eyeball-sparing rate
- timeFrame
- 5 years after chemotherapy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * diagnosed as retinoblastoma * receiving eyeball-sparing treatment Exclusion Criteria: * disease progression during follow-up
References
Publications (0)
Data not yet available
No reference posted for this study.